TB-500 Frag 17-23

Overview and Mechanism of Action

TB-500 Fragment 17-23 is a seven-amino-acid synthetic peptide corresponding to the sequence spanning positions 17 through 23 of the full 43-amino-acid thymosin beta-4 (Tβ4) molecule. The sequence of this fragment is Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ), which encompasses the central actin-binding motif of thymosin beta-4 — specifically the LKKTET hexapeptide that represents the minimal sequence required for G-actin sequestration activity in peptide competition assays.

The biological importance of this central domain was established through systematic deletion and alanine-scanning mutagenesis studies of full-length Tβ4, which demonstrated that the LKKTET motif is necessary for actin monomer binding, and that shorter or mutated versions of this sequence lose G-actin sequestration capacity. The fragment's mechanism of action is therefore understood primarily through the actin-binding biology of its parent molecule: by sequestering G-actin monomers, the fragment can in principle modulate the dynamic equilibrium between monomeric and filamentous actin, influencing the cytoskeletal organization that underlies cell migration, polarity, and mechanosensing.

Research interest in the isolated fragment, as distinct from full-length Tβ4, centers on the question of which biological activities of the parent molecule are attributable specifically to the actin-binding domain versus the N-terminal tetrapeptide (Ac-SDKP, with its anti-inflammatory and hematopoietic effects) or the C-terminal regions that have been proposed to interact with other binding partners. By studying the isolated fragment, researchers can potentially dissect the contribution of actin sequestration to the overall biological effects observed with full-length Tβ4. Additionally, the smaller size of the fragment (approximately 800 Da versus Tβ4's ~4.9 kDa) confers different pharmacokinetic properties, including potentially superior tissue penetration and differing proteolytic stability profiles.

Research History and Development

The characterization of the Tβ4 actin-binding domain was accomplished through structural biology and biochemical studies in the 1990s and early 2000s. Crystallographic and NMR structural studies of Tβ4 in complex with G-actin revealed the molecular details of the LKKTET-actin interface, establishing a framework for understanding which residues are critical for binding affinity. Mutational analyses published by Hannappel, Huff, Safer, and others in biochemistry and cell biology journals documented the loss-of-function consequences of mutations within this region.

Research on isolated actin-binding peptides from Tβ4 has examined their effects on cell migration in vitro, wound healing in ex vivo models, and actin polymerization kinetics in cell-free systems. The fragment has attracted research interest in the context of therapeutic peptide development, where smaller, more economically synthesized fragments retaining key biological activities of a parent protein may offer development advantages. For broader context on the parent molecule's research history, see our /learn/tb-500 article.

Typical Research Parameters

In in vitro actin sequestration assays, the LKKTET-containing fragment is typically tested in the nanomolar to micromolar range using pyrene-actin fluorescence polymerization assays, where the compound's ability to delay actin polymerization kinetics is quantified. Cell migration assays (scratch wound assay, transwell migration assay) using endothelial cells, fibroblasts, or keratinocytes are employed at peptide concentrations of 0.1–10 μM. Comparison experiments using full-length Tβ4 and the isolated fragment at equimolar concentrations allow dissection of which activities are attributable to the core actin-binding domain. In vivo studies in rodent wound healing models have employed the fragment at doses of 1–100 mcg per animal via subcutaneous or topical routes. For research use only.

Storage Requirements

TB-500 Fragment 17-23 as a lyophilized heptapeptide should be stored at -20°C, protected from light and moisture. Its small size renders it more susceptible to hydrolysis and other chemical degradation reactions than the larger parent molecule, though its lack of methionine residues removes one common oxidation liability. Reconstitution with sterile water or physiological buffer should produce a clear solution; store at 2–8°C and use within 14 days. Prepare aqueous solutions at slightly acidic pH (5–6) if extended stability is required. Avoid freeze-thaw cycling of reconstituted solutions.

Safety Notes and Research Considerations

As a fragment of an endogenous peptide, TB-500 Fragment 17-23 is anticipated to have a favorable basic safety profile, though its specific pharmacokinetics and in vivo biological effects may differ meaningfully from the parent molecule. Researchers should not assume that the activity profile of the fragment is simply a scaled-down version of full-length Tβ4; the absence of the N-terminal Ac-SDKP sequence, in particular, removes anti-inflammatory and hematopoietic regulatory activity that is attributed to that domain. Peptide purity verification by HPLC-MS is recommended before use. This compound is for research purposes only and is not approved for therapeutic use.